Answers are grounded in this paper and cite their sources.
Persistent infection with high-risk human papillomavirus (HR-HPV) is the principal etiological driver of cervical cancer, making accurate HPV detection central to contemporary screening strategies. This study compared three molecular assays-INNO-LiPA HPV Genotyping Extra, Cobas 4800 HPV, and Amplicor HPV-using overlapping cervical-sample subsets from Algerian women at increased risk of cervical disease. Among the 94 specimens tested by both INNO-LiPA and Cobas, HR-HPV was detected in 54.3% and 29.8%, respectively; INNO-LiPA also identified HPV16 and HPV18 more frequently. In the 18-specimen subset tested by all three assays, HR-HPV positivity was 27.8% with INNO-LiPA, 33.3% with Cobas, and 50.0% with Amplicor. Pairwise agreement ranged from weak to substantial (κ=0.116-0.667), and discordance was significantly associated with multiple HPV infections (OR=5.88, 95% CI 1.29-26.85; p=0.012). HR-HPV positivity was more frequent in specimens with abnormal cytology, with the strongest association observed for INNO-LiPA (OR=4.9, 95% CI 1.5-15.9; p=0.005). Using the study-defined composite reference classification, INNO-LiPA showed higher sensitivity (93%) but lower specificity (62%) than Cobas (71% and 88%, respectively). These findings demonstrate substantial assay-dependent variation in HR-HPV detection and highlight the value of detailed genotyping for epidemiological investigation, while supporting the use of clinically validated HR-HPV assays for screening applications.
No takes yet. Share an insight, caveat, or question.
Masdoua et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: